| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/JPHP.12387 |
| P698 | PubMed publication ID | 26059702 |
| P2093 | author name string | Sotiris Antoniou | |
| P2860 | cites work | Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines | Q24632872 |
| Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines | Q24633053 | ||
| Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban | Q26864411 | ||
| Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients | Q28190844 | ||
| Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban--an oral, direct factor Xa inhibitor--are not affected by aspirin | Q28200198 | ||
| In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939--an oral, direct Factor Xa inhibitor | Q28238054 | ||
| A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement | Q28274872 | ||
| Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC) | Q28292426 | ||
| Rivaroxaban versus warfarin in nonvalvular atrial fibrillation | Q29614696 | ||
| Ticagrelor versus clopidogrel in patients with acute coronary syndromes | Q29619002 | ||
| Oral rivaroxaban for symptomatic venous thromboembolism | Q29620160 | ||
| Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines | Q33399576 | ||
| Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies. | Q50048963 | ||
| New Anticoagulants | Q56003310 | ||
| Treatment of Proximal Deep-Vein Thrombosis With the Oral Direct Factor Xa Inhibitor Rivaroxaban (BAY 59-7939): The ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) Study | Q56680969 | ||
| Rivaroxaban in patients with a recent acute coronary syndrome | Q34231902 | ||
| Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines | Q34252907 | ||
| Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor | Q34381344 | ||
| Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor | Q34455896 | ||
| BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study | Q34561970 | ||
| Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement | Q34564159 | ||
| Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects | Q34605304 | ||
| Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial | Q34607209 | ||
| The mechanism of action of rivaroxaban – an oral, direct Factor Xa inhibitor – compared with other anticoagulants | Q34624001 | ||
| Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty | Q34789112 | ||
| Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty | Q34789118 | ||
| Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial | Q34789474 | ||
| Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines | Q35752573 | ||
| Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor | Q36988001 | ||
| Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies | Q37363885 | ||
| Practical guidance for using rivaroxaban in patients with atrial fibrillation: balancing benefit and risk | Q37641965 | ||
| Novel anticoagulants for stroke prevention in atrial fibrillation: current clinical evidence and future developments | Q37818783 | ||
| Reversal of antithrombotic agents | Q37998377 | ||
| The cost-effectiveness of oral direct factor Xa inhibitors compared with low-molecular-weight heparin for the prevention of venous thromboembolism prophylaxis in total hip or knee replacement surgery. | Q38102637 | ||
| Laboratory testing of rivaroxaban in routine clinical practice: when, how, and which assays | Q38112792 | ||
| Cost-effectiveness of new oral anticoagulants in the prevention of stroke in patients with atrial fibrillation | Q38129608 | ||
| Practical management of rivaroxaban for the treatment of venous thromboembolism | Q38140693 | ||
| A new paradigm shift in antithrombotic therapy | Q38155157 | ||
| The discovery of rivaroxaban: translating preclinical assessments into clinical practice. | Q38170106 | ||
| The effect of food on the absorption and pharmacokinetics of rivaroxaban | Q39457890 | ||
| Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. | Q40447131 | ||
| Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects | Q41904888 | ||
| Rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--has no clinically relevant interaction with naproxen | Q42123361 | ||
| Effect of co-administration of rivaroxaban and clopidogrel on bleeding time, pharmacodynamics and pharmacokinetics: a phase I study | Q42585790 | ||
| "Triple therapy" rather than "triple threat": a meta-analysis of the two antithrombotic regimens after stent implantation in patients receiving long-term oral anticoagulant treatment | Q43692725 | ||
| The influence of age and gender on the pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct Factor Xa inhibitor | Q43970129 | ||
| Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation | Q44785030 | ||
| Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. | Q45962608 | ||
| In vitro metabolism of rivaroxaban, an oral, direct factor Xa inhibitor, in liver microsomes and hepatocytes of rats, dogs, and humans | Q46131618 | ||
| Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans | Q46131621 | ||
| A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study | Q46487261 | ||
| Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939--an oral, direct Factor Xa inhibitor--after multiple dosing in healthy male subjects | Q46835939 | ||
| Prasugrel versus clopidogrel in patients with acute coronary syndromes | Q46915044 | ||
| Oral rivaroxaban for the treatment of symptomatic pulmonary embolism | Q49168967 | ||
| P433 | issue | 8 | |
| P921 | main subject | thromboembolism | Q891391 |
| P304 | page(s) | 1119-1132 | |
| P577 | publication date | 2015-06-09 | |
| P1433 | published in | Journal of Pharmacy and Pharmacology | Q10532762 |
| P1476 | title | Rivaroxaban for the treatment and prevention of thromboembolic disease | |
| P478 | volume | 67 |
| Q40506281 | Identification and characterization of antibacterial compound(s) of cockroaches (Periplaneta americana). |
| Q50193651 | Impaired Rivaroxaban Clearance in Mild Renal Insufficiency With Verapamil Coadministration: Potential Implications for Bleeding Risk and Dose Selection. |
| Q92604514 | Protective effect of rivaroxaban on arteriosclerosis obliterans in rats through modulation of the toll-like receptor 4/NF-κB signaling pathway |
| Q47134331 | Successful treatment with rivaroxaban of cerebral venous thrombosis and bone marrow necrosis induced by pegaspargase: A case report and literature review |
Warning: Trying to access array offset on value of type null in /home/httpd/vhosts/renenyffenegger.ch/opendata.renenyffenegger.ch/Wikimedia/Wikidata/entity/main.php on line 1120 Warning: Trying to access array offset on value of type null in /home/httpd/vhosts/renenyffenegger.ch/opendata.renenyffenegger.ch/Wikimedia/Wikidata/entity/main.php on line 1120
Search more.